New hepatitis b drug enters human trials – could it help control the virus?

NCT ID NCT07179575

Recruiting now Disease control Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine, LW231, in people with chronic hepatitis B. The goal is to see if it is safe and can lower the amount of virus in the blood. Some participants will get LW231 alone, others will get it together with standard antiviral pills. The trial involves about 270 adults and is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HBV INFECTION

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.